More Access To US Consumers Means More False Claims For COVID-19 Than Other Health Dangers
Executive Summary
While types of unsupported claims were no different than those advertisers made when US was hit it by other widespread health emergencies, digital capabilities made advertisers’ response to COVID-19 different, says Rich Cleland, FTC Consumer Protection Bureau attorney.
You may also be interested in...
Michigan Firm’s Nasal Spray Neither A COVID-19 Treatment Nor For Nasal Use
CofixRx and Sensory Cloud are latest OTC nasal spray marketers FDA warned about fraudulent COVID-19 claims. While the others’ violations were limited to violative claims, CofixRx also warned the active ingredient in its spray is limited to topical use.
COVID-19 Claim Warnings To US CBD Firms? Yes; References To Unlawful Use Of Hemp? No
Seven of nine firms targeted in US regulators’ recent warning letters about unlawful COVID-19 claims are offering supplements containing hemp ingredients. Former naturopathic physician sentenced to prison and probation for conviction on charges linked to offering bogus COVID-19 treatments.
Xlear Admits Referencing Research, Avers Studies Support Saline Nasal Spray’s COVID-19 Efficacy
Firm responds to a complaint DoJ filed for FTC. Founder and president Nathan Jones continues criticism that FTC is attempting to silence research-backed advertising for alternatives to pharmaceuticals public health agencies promote for preventing or treating COVID-19.